HBsAg Decline and HBeAg Seroconversion Following 48 Weeks Peg-interferon-alpha Treatment in Patients With E Antigen Positive Chronic Hepatitis B After Nucleoside Analogue Maintenance Therapy Compared to Continuing Nucleoside Analogue Treatment

Trial Profile

HBsAg Decline and HBeAg Seroconversion Following 48 Weeks Peg-interferon-alpha Treatment in Patients With E Antigen Positive Chronic Hepatitis B After Nucleoside Analogue Maintenance Therapy Compared to Continuing Nucleoside Analogue Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top